Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | RHEB | Q15382 | 5/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | MC5R | P33032 | 1/20 | 0.38 |
| ▸ | MC3R | P41968 | 1/20 | 0.38 |
| ▸ | MC1R | Q01726 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3611191 | 1.00 | GRIN1 (0.51) | GRIN1RHEBSMYD3JAK2DRD4 | |
| SCHEMBL3603094 | 1.00 | GRIN1 (0.51) | GRIN1RHEBSMYD3JAK2DRD4 | |
| SCHEMBL3607343 | 0.93 | GRIN1 (0.49) | GRIN1RHEBSMYD3PARP1 | |
| SCHEMBL3597666 | 0.93 | GRIN1 (0.49) | GRIN1RHEBSMYD3PARP1 | |
| SCHEMBL3597664 | 0.93 | GRIN1 (0.49) | GRIN1RHEBSMYD3PARP1 | |
| SCHEMBL3605718 | 0.93 | GRIN1 (0.54) | GRIN1RHEBSMYD3NUDT1 | |
| Trifluoroacetic Acid SCHEMBL3612509 | 0.92 | GRIN1 (0.47) | GRIN1RHEBSMYD3JAK2DRD4 | |
| SCHEMBL3607893 | 0.92 | GRIN1 (0.48) | GRIN1RHEBSMYD3 | |
| SCHEMBL3596393 | 0.84 | PYGL (0.50) | SMYD3JAK2DRD4KDRPARP1 | |
| SCHEMBL3615337 | 0.84 | PYGL (0.50) | SMYD3JAK2DRD4KDRPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | GRIN1 650/4885RHEB 2282/4885SMYD3 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.